ES2051754T3 - Uso de derivados cetonicos en el tratamiento de la depresion. - Google Patents

Uso de derivados cetonicos en el tratamiento de la depresion.

Info

Publication number
ES2051754T3
ES2051754T3 ES87311082T ES87311082T ES2051754T3 ES 2051754 T3 ES2051754 T3 ES 2051754T3 ES 87311082 T ES87311082 T ES 87311082T ES 87311082 T ES87311082 T ES 87311082T ES 2051754 T3 ES2051754 T3 ES 2051754T3
Authority
ES
Spain
Prior art keywords
depression
treatment
methyl
ketonic derivatives
ketonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87311082T
Other languages
English (en)
Inventor
Michael Brian Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2051754T3 publication Critical patent/ES2051754T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emergency Protection Circuit Devices (AREA)
  • Connection Of Batteries Or Terminals (AREA)
  • Saccharide Compounds (AREA)
  • Electrotherapy Devices (AREA)

Abstract

LA INVENCION SE REFIERE AL EMPLEO DE 1,2,3,9-TETRAHIDRO-9-METIL -3-[(2 METIL-1H-IMIDAZOL-1-IL)METIL]-4H-CARBAZOL-4-ONA Y SUS SALES Y SOLVATOS FISIOLOGICAMENTE ACEPTABLES, EN EL TRATAMIENTO DE LA DEPRESION.
ES87311082T 1986-12-17 1987-12-16 Uso de derivados cetonicos en el tratamiento de la depresion. Expired - Lifetime ES2051754T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868630071A GB8630071D0 (en) 1986-12-17 1986-12-17 Medicaments

Publications (1)

Publication Number Publication Date
ES2051754T3 true ES2051754T3 (es) 1994-07-01

Family

ID=10609112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87311082T Expired - Lifetime ES2051754T3 (es) 1986-12-17 1987-12-16 Uso de derivados cetonicos en el tratamiento de la depresion.

Country Status (18)

Country Link
US (1) US4835173A (es)
EP (1) EP0276559B1 (es)
JP (1) JP2732844B2 (es)
KR (1) KR880007073A (es)
AT (1) ATE79031T1 (es)
AU (1) AU608794B2 (es)
CY (1) CY1693A (es)
DE (1) DE3780940T2 (es)
DK (1) DK662787A (es)
ES (1) ES2051754T3 (es)
GB (1) GB8630071D0 (es)
GR (1) GR3005682T3 (es)
HK (1) HK36593A (es)
IE (1) IE60135B1 (es)
IL (1) IL84844A0 (es)
NZ (1) NZ222949A (es)
PH (1) PH25503A (es)
ZA (1) ZA879458B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246941A (en) 1986-12-17 1993-09-21 Glaxo Group Limited Method for the treatment of depression
DE3788057T2 (de) * 1986-12-17 1994-03-03 Glaxo Group Ltd Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
US5221687A (en) * 1988-09-01 1993-06-22 Glaxo Group Limited Medicaments
GB8820653D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
US5180728A (en) * 1989-09-25 1993-01-19 Fujisawa Pharmaceutical Company, Ltd. Pyrimidoindole derivatives and processes for preparation thereof
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
WO2000051582A2 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
ES2204358T1 (es) * 2000-10-30 2004-05-01 Teva Pharmaceutical Industries Ltd. Nuevas formas de cristal y de disolvente de hidrocloruro de ondasetron y procedimientos para su preparacion.
EP1207160A1 (en) * 2000-11-20 2002-05-22 Hanmi Pharm. Co., Ltd. Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)-methyl)-4H-carbazol-4-one
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
ES2219201T1 (es) * 2001-01-11 2004-12-01 Teva Pharmaceutical Industries Ltd. Procedimiento mejorado para la preparacion de ondansetron clorhidrato dihidrato puro.
MXPA04010846A (es) * 2002-04-29 2005-01-25 Biogal Gyogyszergyar Proceso para preparar 1, 2, 3, 9-tetrahidro -9- metil-3 -[(2-metil -1h-imidazol -1-il) metil]- 4h- carbazol -4- ona.
US20040019093A1 (en) * 2002-04-30 2004-01-29 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
US20110034442A1 (en) * 2007-08-08 2011-02-10 Jaun Jose Legarda Ibanez Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
US20210267251A1 (en) * 2018-06-21 2021-09-02 Societe Des Produits Nestle S.A. Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN158970B (es) * 1981-06-09 1987-02-28 Ici Plc
HU193592B (en) * 1984-01-25 1987-11-30 Glaxo Group Ltd Process for producing tetrahydro-carbazolone derivatives
GB8401888D0 (en) * 1984-01-25 1984-02-29 Glaxo Group Ltd Heterocyclic compounds
EP0385517B1 (en) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Medicaments for the treatment of emesis
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions

Also Published As

Publication number Publication date
JPS63165314A (ja) 1988-07-08
IE60135B1 (en) 1994-06-01
EP0276559A2 (en) 1988-08-03
CY1693A (en) 1994-01-14
KR880007073A (ko) 1988-08-26
EP0276559A3 (en) 1989-10-18
DE3780940T2 (de) 1992-12-24
US4835173A (en) 1989-05-30
DK662787A (da) 1988-06-18
ATE79031T1 (de) 1992-08-15
DK662787D0 (da) 1987-12-16
ZA879458B (en) 1988-11-30
EP0276559B1 (en) 1992-08-05
IE873415L (en) 1988-06-17
DE3780940D1 (de) 1992-09-10
HK36593A (en) 1993-04-23
IL84844A0 (en) 1988-06-30
PH25503A (en) 1991-07-24
GB8630071D0 (en) 1987-01-28
NZ222949A (en) 1997-06-24
AU608794B2 (en) 1991-04-18
AU8261787A (en) 1988-06-23
JP2732844B2 (ja) 1998-03-30
GR3005682T3 (es) 1993-06-07

Similar Documents

Publication Publication Date Title
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
ES2170102T3 (es) Aminociclohexilesteres y utilizacion de los mismos.
ES2162268T3 (es) Composiciones cosmeticas a base de pirazolin-4,5-dionas, nuevas pirazolin-4,5-dionas, procedimientos de preparacion y utilizaciones.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
YU26691A (sh) BORNO KISELINSKI ADUKTI RENIJUM DIOKSIM I TEHNICIJUM-99 m DIOKSIM KOMPLEKSA I PRIBOR ZA MARKIRANJE SA TEHNICIJUMOM 99 m I/ILI RADIONUKLEIDOM RENIJUMA
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
SE8501709D0 (sv) Improvements in or relating to intrleukin therapy
ES2177695T3 (es) Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
DK0574457T3 (da) Antiviral nucleosidkombination
PL268927A1 (en) Method of obtaining novel derivatives of benzimidazole
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
ES2052585T3 (es) Uso de derivados cetonicos en el tratamiento de desordenes cognitivos.
DK76582A (da) Antimycotiske midler
ES2118955T3 (es) Derivados de dolastatina.
CY1693A (en) Use of ketone derivatives in the treatment of depression
ES2180573T3 (es) Uso de derivados de indol como antagonistas de 5ht1.
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
IT1213323B (it) Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
ATE40987T1 (de) Acetylenische phenoxypropanolderivate und pharmazeutische zusammensetzungen fuer die behandlung von bluthochdruck.
ES2086409T3 (es) Imidazolinas sustituidas en posicion 2 y preparacion y uso de las mismas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 276559

Country of ref document: ES